Seres Ther­a­peu­tics sheds about 160 jobs to fo­cus on com­mer­cial C. diff pill

Seres Ther­a­peu­tics will end most R&D work to fo­cus re­sources on its com­mer­cial prod­uct in a move that will re­sult in let­ting go about 160 work­ers, or 41% of the staff, the biotech said Thurs­day morn­ing.

The Boston biotech said it will place pri­or­i­ty on its pill Vow­st, which se­cured FDA ap­proval in April for pa­tients re­cov­er­ing from re­peat­ing in­fec­tions of Clostrid­ioides dif­fi­cile, com­mon­ly called C. diff.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.